260 related articles for article (PubMed ID: 26304061)
1. Epicutaneous immunotherapy with a hypoallergenic Bet v 1 suppresses allergic asthma in a murine model.
Siebeneicher S; Reuter S; Wangorsch A; Krause M; Foetisch K; Heinz A; Naito S; Reuter A; Taube C; Vieths S; Scheurer S; Toda M
Allergy; 2015 Dec; 70(12):1559-68. PubMed ID: 26304061
[TBL] [Abstract][Full Text] [Related]
2. Epicutaneous immune modulation with Bet v 1 plus R848 suppresses allergic asthma in a murine model.
Siebeneicher S; Reuter S; Krause M; Wangorsch A; Maxeiner J; Wolfheimer S; Schülke S; Naito S; Heinz A; Taube C; Vieths S; Scheurer S; Toda M
Allergy; 2014 Mar; 69(3):328-37. PubMed ID: 24329861
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy.
Kahlert H; Suck R; Weber B; Nandy A; Wald M; Keller W; Cromwell O; Fiebig H
Int Arch Allergy Immunol; 2008; 145(3):193-206. PubMed ID: 17912007
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of sublingual vectorized recombinant Bet v 1a in a mouse model of birch pollen allergic asthma.
Tourdot S; Airouche S; Berjont N; Moussu H; Betbeder D; Nony E; Bordas-Le Floch V; Baron-Bodo V; Mascarell L; Moingeon P
Vaccine; 2013 May; 31(23):2628-37. PubMed ID: 23583462
[TBL] [Abstract][Full Text] [Related]
5. T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies.
Vrtala S; Akdis CA; Budak F; Akdis M; Blaser K; Kraft D; Valenta R
J Immunol; 2000 Dec; 165(11):6653-9. PubMed ID: 11086111
[TBL] [Abstract][Full Text] [Related]
6. Quality and potency profile of eight recombinant isoallergens, largely mimicking total Bet v 1-specific IgE binding of birch pollen.
Seutter von Loetzen C; Reuter A; Spiric J; Schulenborg T; Bellinghausen I; Völker E; Vogel L; Rösch P; Schiller D
Clin Exp Allergy; 2019 May; 49(5):712-723. PubMed ID: 30706562
[TBL] [Abstract][Full Text] [Related]
7. Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1.
Mahler V; Vrtala S; Kuss O; Diepgen TL; Suck R; Cromwell O; Fiebig H; Hartl A; Thalhamer J; Schuler G; Kraft D; Valenta R
Clin Exp Allergy; 2004 Jan; 34(1):115-22. PubMed ID: 14720271
[TBL] [Abstract][Full Text] [Related]
8. Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season.
van Hage-Hamsten M; Kronqvist M; Zetterström O; Johansson E; Niederberger V; Vrtala S; Grönlund H; Grönneberg R; Valenta R
J Allergy Clin Immunol; 1999 Nov; 104(5):969-77. PubMed ID: 10550741
[TBL] [Abstract][Full Text] [Related]
9. Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination.
Vrtala S; Fohr M; Campana R; Baumgartner C; Valent P; Valenta R
Vaccine; 2011 Mar; 29(11):2140-8. PubMed ID: 21215346
[TBL] [Abstract][Full Text] [Related]
10. Intranasal treatment with a recombinant hypoallergenic derivative of the major birch pollen allergen Bet v 1 prevents allergic sensitization and airway inflammation in mice.
Wiedermann U; Herz U; Baier K; Vrtala S; Neuhaus-Steinmetz U; Bohle B; Dekan G; Renz H; Ebner C; Valenta R; Kraft D
Int Arch Allergy Immunol; 2001 Sep; 126(1):68-77. PubMed ID: 11641608
[TBL] [Abstract][Full Text] [Related]
11. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1.
Gafvelin G; Thunberg S; Kronqvist M; Grönlund H; Grönneberg R; Troye-Blomberg M; Akdis M; Fiebig H; Purohit A; Horak F; Reisinger J; Niederberger V; Akdis CA; Cromwell O; Pauli G; Valenta R; van Hage M
Int Arch Allergy Immunol; 2005 Sep; 138(1):59-66. PubMed ID: 16103688
[TBL] [Abstract][Full Text] [Related]
12. Frequent occurrence of T cell-mediated late reactions revealed by atopy patch testing with hypoallergenic rBet v 1 fragments.
Campana R; Moritz K; Marth K; Neubauer A; Huber H; Henning R; Blatt K; Hoermann G; Brodie TM; Kaider A; Valent P; Sallusto F; Wöhrl S; Valenta R
J Allergy Clin Immunol; 2016 Feb; 137(2):601-609.e8. PubMed ID: 26518092
[TBL] [Abstract][Full Text] [Related]
13. Development and evaluation of a sublingual tablet based on recombinant Bet v 1 in birch pollen-allergic patients.
Nony E; Bouley J; Le Mignon M; Lemoine P; Jain K; Horiot S; Mascarell L; Pallardy M; Vincentelli R; Leone P; Roussel A; Batard T; Abiteboul K; Robin B; de Beaumont O; Arvidsson M; Rak S; Moingeon P
Allergy; 2015 Jul; 70(7):795-804. PubMed ID: 25846209
[TBL] [Abstract][Full Text] [Related]
14. Characterization of wild-type recombinant Bet v 1a as a candidate vaccine against birch pollen allergy.
Batard T; Didierlaurent A; Chabre H; Mothes N; Bussières L; Bohle B; Couret MN; Ball T; Lemoine P; Focks Tejkl M; Chenal A; Clément G; Dupont F; Valent P; Krauth MT; André C; Valenta R; Moingeon P
Int Arch Allergy Immunol; 2005 Mar; 136(3):239-49. PubMed ID: 15722633
[TBL] [Abstract][Full Text] [Related]
15. Prevention of allergen-specific IgE production and suppression of an established Th2-type response by immunization with DNA encoding hypoallergenic allergen derivatives of Bet v 1, the major birch-pollen allergen.
Hochreiter R; Stepanoska T; Ferreira F; Valenta R; Vrtala S; Thalhamer J; Hartl A
Eur J Immunol; 2003 Jun; 33(6):1667-76. PubMed ID: 12778485
[TBL] [Abstract][Full Text] [Related]
16. Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wild-type by skin prick and intradermal testing: results obtained in a French population.
Pauli G; Purohit A; Oster JP; De Blay F; Vrtala S; Niederberger V; Kraft D; Valenta R
Clin Exp Allergy; 2000 Aug; 30(8):1076-84. PubMed ID: 10931114
[TBL] [Abstract][Full Text] [Related]
17.
Aglas L; Bethanis A; Chrusciel P; Stolz F; Gruen M; Jaakkola UM; Jongejan L; Yatkin E; Van Ree R
Front Immunol; 2020; 11():2118. PubMed ID: 33013894
[TBL] [Abstract][Full Text] [Related]
18. Folded or Not? Tracking Bet v 1 Conformation in Recombinant Allergen Preparations.
Husslik F; Hanschmann KM; Krämer A; Seutter von Loetzen C; Schweimer K; Bellinghausen I; Treudler R; Simon JC; Vogel L; Völker E; Randow S; Reuter A; Rösch P; Vieths S; Holzhauser T; Schiller D
PLoS One; 2015; 10(7):e0132956. PubMed ID: 26186356
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis.
Pauli G; Larsen TH; Rak S; Horak F; Pastorello E; Valenta R; Purohit A; Arvidsson M; Kavina A; Schroeder JW; Mothes N; Spitzauer S; Montagut A; Galvain S; Melac M; André C; Poulsen LK; Malling HJ
J Allergy Clin Immunol; 2008 Nov; 122(5):951-60. PubMed ID: 19000581
[TBL] [Abstract][Full Text] [Related]
20. Induction of IgE antibodies in mice and rhesus monkeys with recombinant birch pollen allergens: different allergenicity of Bet v 1 and Bet v 2.
Vrtala S; Mayer P; Ferreira F; Susani M; Sehon AH; Kraft D; Valenta R
J Allergy Clin Immunol; 1996 Nov; 98(5 Pt 1):913-21. PubMed ID: 8939154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
